Scale Data
Ecological Harm Reduction (EHR) Framework
Core argument: Drug prohibition is a climate crisis driver. Aerial herbicide spraying of coca and cannabis crops destroys rainforest and contaminates watersheds. Forced displacement of coca and poppy farmers drives deforestation as displaced communities clear new land. Militarised eradication programmes produce ecological harms at scale that are systematically excluded from climate accounting.
Buen Vivir: Buen Vivir (Good Living) — an Andean Indigenous philosophy of living in harmony with nature and community — is proposed as an alternative development framework to conventional economic growth models. Applied to drug policy: coca cultivation embedded in Buen Vivir frameworks is not a criminal enterprise to be eradicated but an ecological and cultural practice that supports sustainable livelihoods. Eradication is the failure mode; integration is the alternative.
Coca reframe: Coca as described in From Forest to Dust (2025): an agent of socioeconomic prosperity, racial justice, and ecological balance in Andean communities. Coca cultivation is labour-intensive, supports small-scale agriculture, and is compatible with agroforestry. Eradication for the benefit of cocaine-consuming markets in the Global North imposes ecological and economic costs on Andean communities without their consent.
Psychedelic parallel: The EHR framework applies to psychedelic markets: psilocybin mushroom cultivation is ecologically benign when conducted by small-scale Indigenous cultivators in Oaxaca. Pharmaceutical-track synthetic production removes this ecological relationship entirely. Bufo alvarius toad extraction for 5-MeO-DMT is ecologically harmful. The regulatory framework that incentivises synthetic production over traditional cultivation is not ecologically neutral — it reshapes ecological relationships in ways that current regulatory frameworks do not account for.
Producer-Region Implications — Psychedelic Compounds
Oaxacan communities (Mazatec, Zapotec) are the primary source of psilocybin mushroom cultivation knowledge that entered Western markets through Wasson's 1957 extraction. As US legal market for psilocybin develops, synthetic pharmaceutical-track production (Compass COMP360) will displace traditional Oaxacan cultivation from any legal market benefit. Monitor for any Mexican government response to US psychedelic commercialisation.
Gabon is the primary iboga source country and has restricted export (Law No. 002/2019). Commercial ibogaine development (MindMed, atai/DemeRx) using synthetic ibogaine argues it is not using Gabonese resources — but the pharmacological knowledge originated in Bwiti tradition. Monitor for any Gabonese government response to international ibogaine commercialisation.
Amazonian countries (Peru, Brazil, Ecuador, Colombia) host the communities whose ayahuasca knowledge is being commercialised. Peru has a National Registry of Healers and has taken some steps to protect ayahuasca tourism. Monitor for any regional coordination among Amazonian countries on psychedelic commercialisation governance.
The Sonoran Desert toad (Bufo alvarius) whose venom contains 5-MeO-DMT is found in Mexico and the southwestern US. Mexico's environmental authorities have noted population stress. Monitor for any CITES listing proposal or Mexican government regulation of 5-MeO-DMT extraction.
Five UNDP Development Domains
Rural development, poverty reduction, and economic security for people working in illegal drug economies during market transition. Coca farmers in Colombia, poppy farmers in Afghanistan, psilocybin mushroom cultivators in Oaxaca — all face livelihood disruption when markets shift. Just transition requires alternative livelihood support, not just enforcement withdrawal.
Psychedelic market relevance: Psilocybin mushroom cultivation is a livelihood for Indigenous and rural communities in Oaxaca, Chiapas, and other regions. As pharmaceutical-track psilocybin is produced synthetically in licensed facilities, traditional cultivators face economic marginalisation. Monitor for any US jurisdiction creating pathways for traditional cultivators in licensed frameworks.
Organised crime, land reform, institutional corruption, conflict financed by drug trade revenues, and enforcement militarisation. Drug prohibition finances organised crime globally. Market transition that is too slow, too partial, or creates new monopolies can redirect rather than eliminate organised crime involvement.
Psychedelic market relevance: At current psychedelic market scale, organised crime involvement is limited. Monitor for any evidence of trafficking network adaptation as market grows. DEA scheduling decisions and FDA approval timelines affect whether legal supply develops fast enough to foreclose illicit supply.
Harm reduction, treatment access, essential medicines availability, and gender-integrated health policy. UNDP recommendation: integrate gender across all policy dimensions — not as a standalone section but as a cross-cutting criterion. Women, transgender people, and non-binary people face specific drug-related harms that gender-neutral frameworks systematically miss.
Psychedelic market relevance: Psychedelic-assisted therapy for PTSD has documented efficacy for survivors of sexual violence — a population that is predominantly women. Access barriers (cost, geographical, regulatory) disproportionately affect this population. Monitor for whether any equity framework specifically addresses gender-based access barriers to psychedelic therapy.
Rights of people who use drugs, Indigenous Peoples, women, LGBTIQ+ people, sex workers, and people in detention. Prohibition systematically violates the human rights of people who use drugs — through criminalisation, forced treatment, and incarceration. Legal market transition must be evaluated against human rights standards, not just health outcomes.
Psychedelic market relevance: Psychedelic use is already decriminalised or tolerated in several jurisdictions. Monitor for whether decriminalisation extends to all users equally, or whether enforcement disparities persist post-decriminalisation. Oregon Measure 110 repeal (2024) demonstrates that decriminalisation without structural embedding is reversible.
Deforestation, crop eradication (aerial spraying), chemical contamination, climate impacts of prohibition enforcement, and ecological harm from both illegal cultivation and legal production. From Forest to Dust (Rolles & Ryder, 2025) documents prohibition as a climate crisis driver: coca eradication destroys rainforest, herbicide spraying contaminates watersheds, forced displacement drives further deforestation. Buen Vivir framework offers alternative development model.
Psychedelic market relevance: Psilocybin mushroom cultivation has minimal ecological footprint. However, Bufo alvarius toad venom extraction for 5-MeO-DMT is causing documented population stress. Iboga extraction in Gabon creates deforestation pressure. Ayahuasca vine cultivation for export creates monoculture risk. Monitor for any environmental sustainability standard in psychedelic regulatory frameworks.
Diplomatic & International Monitoring
The International Narcotics Control Board (INCB) monitors treaty compliance. State-level psychedelic reform in the US creates treaty tensions — psilocybin is Schedule I under the 1971 Convention on Psychotropic Substances. INCB has historically been critical of cannabis legalisation as treaty-inconsistent. Monitor for any INCB statement or report on US state-level psychedelic reform.
The US State Department's Bureau of International Narcotics and Law Enforcement Affairs (INL) sets US international drug policy positions. Any shift in State Department position on psychedelic reform — from opposition to tolerance to support — is a significant diplomatic signal. Monitor for any INL statement, Congressional testimony, or diplomatic cable release touching psychedelic scheduling.
The 68th CND independent expert panel is examining whether the three UN drug control treaties can be interpreted to permit the range of drug policy approaches states are implementing. A panel finding that state-level psychedelic regulation is treaty-consistent would remove the primary legal argument against federal accommodation. A finding that it is treaty-inconsistent would put states in direct conflict with federal treaty obligations.
Monitor for any statement by Colombia, Mexico, Peru, Bolivia, Ecuador, or Gabon governments on US psychedelic regulatory developments. These are the primary producer-region states for psilocybin, coca, iboga, and ayahuasca compounds. Their positions on US commercialisation of these compounds — and whether they are consulted or ignored — is a key development lens indicator.
UNDP Strategic Recommendations — Monitoring Targets
68th CND Independent Expert Panel
Mandate: Resolving tensions between the three UN drug control treaties (1961 Single Convention, 1971 Convention on Psychotropic Substances, 1988 Convention) and human rights law, sustainable development frameworks, and public health obligations
Live international legal mechanism. Transform is actively contributing. The panel's outputs could provide authoritative guidance on whether state-level psychedelic regulation is consistent with treaty obligations — the primary legal argument used by federal governments to resist state reform.
Transform contribution: Steve Rolles and Transform have submitted evidence and analysis to the panel process
The too-parochial pattern is not a gap in US psychedelic policy — it is the defining characteristic. Every current framework is designed as if psilocybin mushrooms grow in a vacuum, unconnected to the Mazatec communities where Western access originated, the Oaxacan cultivators who produce them, and the global drug trade dynamics that US scheduling decisions shape. The Ecological Harm Reduction framework from Forest to Dust (2025) extends this further: prohibition itself is a climate crisis driver, and the transition to legal markets must account for ecological impacts that current frameworks ignore entirely.
The concrete producer-region implications are compound-specific. Psilocybin: Oaxacan cultivators face marginalisation as pharmaceutical-track synthetic production captures the legal market. Iboga: Gabon’s export restriction provides partial protection, but synthetic ibogaine development bypasses it. 5-MeO-DMT: Sonoran Desert toad populations face documented stress; synthetic claims by GH Research are unverified at commercial scale. Ayahuasca: no ABS framework exists for any Amazonian nation’s ayahuasca knowledge as Western commercialisation expands.
The 68th CND independent expert panel is the live mechanism where treaty reform, producer-region concerns, and public health obligations intersect. Transform’s active contribution means Observatory findings feed directly into that evidence base. The diplomatic monitoring section — INCB, State Department, producer-region governments — provides the signals that indicate whether the too-parochial pattern is being challenged at the international level or entrenching further.
Subscribe to Development Lens alerts
Receive the Monday 8am HST weekly intelligence digest when new developments are scored for this tab.
We store only the name and email you enter here, and use them only to send this digest. Every email carries an unsubscribe link, which removes the address immediately.